FCGR3A and cancer: Ochi et al. demonstrated that T cells engineered to express a chimeric CD16-CD3 receptor effectively mediate ADCC and proliferate and exhibit superior tumour-suppressive activity compared to NK cells, suggesting their potential as a more durable and effective alternative effector for monoclonal antibody cancer therapies [65].